A drug target is the molecule or structure a treatment acts on and its mechanism of action is how that action produces an effect, and each step from target to patient benefit needs its own evidence.
A drug target is a biological molecule or structure that a treatment acts on, and the mechanism of action explains how that action produces an effect. The National Cancer Institute describes targeted therapy as treatment that targets proteins that control how cancer cells grow, divide and spread, and says most targeted therapies are small-molecule drugs, which are small enough to enter cells and so suit targets inside cells, or monoclonal antibodies, which are designed to attach to specific targets on cancer cells. It describes antibodies that mark cancer cells for the immune system, antibodies that stop growth or cause self-destruction directly, and antibodies that carry toxins to cancer cells. These are different jobs, so a shared label of targeted does not make the mechanisms interchangeable, and a target that is only an address for delivery need not drive the cancer's growth.
An altered gene or an elevated protein can suggest a target hypothesis; it does not show that inhibiting the target will harm cancer cells selectively, which controlled perturbations of the target test, and safe exposure and appropriate clinical studies answer later questions. Naming a target answers only the first of several questions. Binding is an interaction between molecules and can be shown with a purified protein, which does not show that the compound reaches the protein inside a cell. Target engagement asks whether the interaction occurs in the relevant cells or tissue, and exposure, target location and the cell membrane all bear on it; a blood concentration and a concentration at an intracellular target are different observations. The cellular thermal shift assay of Martinez Molina and colleagues was developed to evaluate drug binding to target proteins in cells and tissue samples, and its authors used it to monitor drug transport and activation, off-target effects and resistance in cancer cell lines. Binding is also different from changing function: a compound can inhibit an enzyme, activate a receptor or deliver a payload, and a binder can leave the target's activity unchanged. Binding assays test an interaction under specified conditions and engagement assays examine the relevant cells or tissue, while a downstream signal measures a biological consequence and is not automatically a direct measure of how much of the target is occupied; growth, death and regrowth assays add further layers. A measured change in signalling, division or survival needs controls that test the proposed explanation, and one positive experiment should not carry the whole claim.
The last step is clinical. Mechanistic plausibility does not show benefit, because the target may also be present in healthy tissue and the useful margin depends on achieved benefit and harm in a stated disease, treatment setting, product and outcome. The National Cancer Institute adds that cancer cells can become resistant to targeted therapy when the target itself changes so the drug can no longer interact with it, or when cells find new ways to grow that do not depend on the target.
Worked example, fictional. An antibody binds protein A on cancer cells, and a growth assay shows no change. Binding is supported under the assay conditions. It has not been shown that protein A drives growth, that the antibody inhibits protein A's function, that a finished payload-bearing product delivers anything, or that the product is safe and beneficial; each of those needs its own evidence. Before saying a drug worked, name the layer that was measured.
Shares Targeted therapy, EGFR.
Shares Targeted therapy, EGFR.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/